NFSG
CMMB

Newbridge Financial Services Group’s Chemomab Therapeutics CMMB Stock Holding History

Newbridge Financial Services Group’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-275
Closed -$985 – 1195
2023
Q3 		$985 Hold
275
– – ﹤0.01% 1159
2023
Q2 		$1.45K Hold
275
– – ﹤0.01% 1175
2023
Q1 		$1.75K Hold
275
– – ﹤0.01% 1214
2022
Q4 		$3.52K Hold
275
– – ﹤0.01% 1127
2022
Q3 		$3K Hold
275
– – ﹤0.01% 1117
2022
Q2 		$4K Hold
275
– – ﹤0.01% 1045
2022
Q1 		$5K Buy
+275
New +$5.42K ﹤0.01% 1090

Other funds holding CMMB

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Newbridge Financial Services Group's CMMB Position: Q4 2023 in Review

Newbridge Financial Services Group sold out of Chemomab Therapeutics (CMMB) in Q4 2023, closing a stake of 275 shares — an estimated $985 sold.

Newbridge Financial Services Group first reported a position in CMMB in Q1 2022 and held it in 7 quarters. The position peaked at $5K in Q1 2022. 17 funds tracked by Wall St. Rank hold CMMB as of Q4 2023.

  • Newbridge Financial Services Group reported no remaining Chemomab Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Newbridge Financial Services Group sold 275 Chemomab Therapeutics shares in Q4 2023, an estimated $985.
  • Newbridge Financial Services Group first reported a position in Chemomab Therapeutics in Q1 2022 and held it in 7 quarters.
  • Newbridge Financial Services Group's Chemomab Therapeutics position peaked at $5K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q4 2023.

Based on Newbridge Financial Services Group's 13F filing for Q4 2023, filed 28 Mar 2024.